Mostrar el registro sencillo del ítem

Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases

dc.contributor.authorBaig M.H.
dc.contributor.authorAhmad K.
dc.contributor.authorSaeed M.
dc.contributor.authorAlharbi A.M.
dc.contributor.authorBarreto G.E.
dc.contributor.authorAshraf G.M.
dc.contributor.authorChoi I.
dc.date.accessioned2020-09-02T22:13:01Z
dc.date.available2020-09-02T22:13:01Z
dc.date.issued2018
dc.identifier10.1016/j.biopha.2018.04.025
dc.identifier.citation103, , 574-581
dc.identifier.issn07533322
dc.identifier.urihttps://hdl.handle.net/20.500.12728/3704
dc.descriptionBioactive peptides are actively involved in different biological functions and importantly contribute to human health, and the use of peptides as therapeutics has a long successful history in disease management. A number of peptides have wide-ranging therapeutic effects, such as antioxidant, antimicrobial, and antithrombotic effects. Neurodegenerative diseases are typically caused by abnormal aggregations of proteins or peptides, and the depositions of these aggregates in or on neurons, disrupt signaling and eventually kill neurons. During recent years, research on short peptides has advanced tremendously. This review offers a brief introduction to peptide based therapeutics and their application in disease management and provides an overview of peptide vaccines, and toxicity related issues. In addition, the importance of peptides in the management of different neurodegenerative diseases and their therapeutic applications is discussed. The present review provides an understanding of peptides and their applications for the management of different diseases, but with focus on neurodegenerative diseases. The role of peptides as anti-cancer, antimicrobial and antidiabetic agents has also been discussed. © 2018 Elsevier Masson SAS
dc.language.isoen
dc.publisherElsevier Masson SAS
dc.subjectAnti-Cancer
dc.subjectEnzymes
dc.subjectNeurodegenerative disorders
dc.subjectPeptide based vaccine
dc.subjectPeptides
dc.subjectStability
dc.subjectBa V peptide
dc.subjectcarnosine
dc.subjectdavunetide
dc.subjectdefensin
dc.subjectdermcidin
dc.subjecthepcidin
dc.subjectpeptide
dc.subjectpeptide vaccine
dc.subjectpolyglutamine
dc.subjectpolypeptide antibiotic agent
dc.subjectprotein p110
dc.subjectQBP1 peptide
dc.subjectunclassified drug
dc.subjectvasoactive intestinal polypeptide
dc.subjectantidiabetic agent
dc.subjectantiinfective agent
dc.subjectantioxidant
dc.subjectpeptide
dc.subjectdegenerative disease
dc.subjectdiabetes mellitus
dc.subjectdrug therapy
dc.subjecthuman
dc.subjectmalignant neoplasm
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectReview
dc.subjecttoxicity
dc.subjectanimal
dc.subjectdegenerative disease
dc.subjectdrug effect
dc.subjectmembrane potential
dc.subjectmetabolism
dc.subjectpathology
dc.subjectphysiology
dc.subjecttreatment outcome
dc.subjectAnimals
dc.subjectAnti-Bacterial Agents
dc.subjectAnti-Infective Agents
dc.subjectAntioxidants
dc.subjectHumans
dc.subjectHypoglycemic Agents
dc.subjectMembrane Potentials
dc.subjectNeurodegenerative Diseases
dc.subjectPeptides
dc.subjectTreatment Outcome
dc.titlePeptide based therapeutics and their use for the treatment of neurodegenerative and other diseases
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85045547202.pdf
Tamaño:
3.333Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem